Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hormonal changes affect the bone and bone marrow cells in a rat model.

D Benayahu1, I Shur, S Ben-Eliyahu

  • 1Department of Cell Biology and Histology, Tel Aviv University, Tel Aviv 69978, Israel. dafnab@post.tau.ac.il

Journal of Cellular Biochemistry
|September 6, 2000
PubMed
Summary

This study examines how removing sex hormones affects bone health and immune cell populations in the bone marrow of rats. Researchers found that hormone loss leads to bone thinning and increased fat cells, while also triggering an rise in specific immune cells. Treatment with estrogen effectively reversed these immune changes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dexmedetomidine promotes metastasis in rodent models of breast, lung, and colon cancers.

British journal of anaesthesia·2018
Same author

Significantly enhanced lung metastasis and reduced organ NK cell functions in diet-induced obese rats.

BMC obesity·2017
Same author

The Osteogenic Compartment of Bone Marrow: Cell Biology and Clinical Application.

Hematology (Amsterdam, Netherlands)·2016
Same author

Stress impairs the efficacy of immune stimulation by CpG-C: Potential neuroendocrine mediating mechanisms and significance to tumor metastasis and the perioperative period.

Brain, behavior, and immunity·2016
Same author

Expression of parathyroid hormone receptor 1 (PTH1-Rc) in bone marrow derived mesenchymal stem cells (MSC).

Journal of stem cells & regenerative medicine·2014
Same author

PGE2 suppresses NK activity in vivo directly and through adrenal hormones: effects that cannot be reflected by ex vivo assessment of NK cytotoxicity.

Brain, behavior, and immunity·2012

Area of Science:

  • Endocrinology and skeletal biology research within osteopenia studies
  • Immunology and bone marrow microenvironment analysis

Background:

The precise mechanisms linking hormonal shifts to skeletal degradation remain poorly understood in aging populations. Prior research has shown that sex steroids influence bone density, yet the specific cellular dynamics within the marrow cavity require further clarification. That uncertainty drove this investigation into the interplay between endocrine status and marrow-resident cell populations. It was already known that estrogen deficiency triggers bone loss, but the concurrent changes in immune cell subsets were not fully characterized. No prior work had resolved whether age-related marrow alterations mirror those induced by surgical hormone depletion. This gap motivated a comparative analysis of young and mature rodent models. Investigators sought to determine if specific lymphoid or myeloid markers respond predictably to hormonal fluctuations. Establishing these relationships provides a clearer picture of how systemic endocrine signals modulate the local bone marrow environment.

Purpose Of The Study:

Keywords:
bone marrowestrogen deficiencyT-lymphocytesadipocytes

Frequently Asked Questions

The researchers propose that estrogen deficiency triggers bone thinning and an increase in marrow fat cells. This process coincides with an expansion of T-lymphoid cells, which the authors suggest is reversed by 17beta-estradiol administration. Progesterone alone does not influence these specific immune cell counts.

The team utilized flow cytometry to analyze cell surface antigens. This technique allowed for the identification of specific markers, including ED-9, CD-44, CD4, and CD5, on lymph-myeloid cells within the marrow. These measurements were taken twelve weeks after the initiation of hormone replacement therapy.

The authors state that the myeloid cells expressing ED-9 or CD-44 were unaffected by ovariectomy or hormone replacement. This stability suggests that these specific myeloid populations do not participate in the hormonal regulation of bone marrow structure observed in this model.

Related Experiment Videos

The study aimed to investigate the effects of gonad hormones and replacement therapy on bone structure and the immune system. Researchers sought to clarify how hormonal fluctuations influence the bone marrow microenvironment. This investigation addressed the lack of data regarding cellular changes following the loss of ovarian function. The team hypothesized that hormonal status dictates the composition of marrow-resident cell populations. By comparing different age groups, the authors intended to isolate the effects of aging from those caused by hormone depletion. The project specifically examined the relationship between bone atrophy and the presence of adipocytes. Furthermore, the researchers evaluated whether hormone replacement could reverse immune cell alterations. This work provides a foundation for understanding the endocrine regulation of skeletal health.

Main Methods:

Review approach involved a two-phase experimental design using F344 rats of varying ages. Researchers performed surgical removal of ovaries to induce a state of hormone deficiency. Control animals underwent sham operations to account for surgical stress. Histological techniques allowed for the assessment of bone structure and marrow composition. Investigators utilized flow cytometry to quantify the expression of specific cell surface antigens on immune cells. Sustained-release pellets delivered 17beta-estradiol and progesterone to the experimental groups. The team monitored the animals for twelve weeks following the initiation of these hormonal treatments. Statistical comparisons between the groups helped clarify the impact of age and hormone status on the marrow microenvironment.

Main Results:

Key findings from the literature indicate that ovariectomy caused severe bone thinning in both young and mature rats. Histological analysis revealed that this bone loss correlated with a significant rise in marrow adipocytes. The study observed an increase in T-lymphoid cells expressing CD4 and CD5 markers following hormone depletion. These immune cell changes occurred alongside the observed skeletal atrophy. Administration of 17beta-estradiol successfully prevented the rise of T-lymphoid cells in the hormone-deficient rats. Progesterone treatment alone showed no effect on these specific immune cell populations. Myeloid cells expressing ED-9 or CD-44 remained stable across all experimental conditions and age groups. The data confirm that hormonal therapy maintains physiological levels to counteract the cellular shifts in the marrow.

Conclusions:

Synthesis and implications suggest that estrogen deficiency directly promotes bone atrophy while simultaneously altering the composition of the bone marrow immune compartment. The authors propose that the observed increase in marrow adipocytes serves as a marker for skeletal deterioration. Findings indicate that T-lymphoid cell expansion is a distinct response to both aging and the loss of ovarian hormones. The data demonstrate that 17beta-estradiol effectively restores these immune cell populations to baseline levels. Conversely, progesterone treatment alone fails to mitigate the lymphoid changes induced by ovariectomy. The researchers conclude that the bone marrow microenvironment remains highly sensitive to circulating estrogen levels throughout maturity. These results highlight a potential pathway where hormonal therapy could modulate immune activity within the skeletal niche. The study confirms that myeloid cell populations remain stable regardless of hormonal status or age.

Flow cytometry data provided the basis for identifying T-lymphoid and myeloid cell subsets. This quantitative approach enabled the researchers to track how specific cell populations shifted in response to ovariectomy and subsequent hormone replacement therapy across different age groups.

The researchers measured the expression of CD4 and CD5 markers on T-lymphoid cells. They observed an augmentation of these cells following ovariectomy, which was distinct from the stable expression levels of myeloid markers like ED-9 and CD-44.

The authors suggest that 17beta-estradiol is the primary agent for reversing T-lymphopoiesis to baseline levels. They imply that maintaining physiological hormone levels is necessary to prevent the cellular shifts associated with bone atrophy in this rodent model.